The news that Qing Ning Group acquired Vitron Medical and Marui Medical at the same time has received moderate discussion on the Internet. After all, there has been a wave of turmoil before.

No matter how amazing it is, it’s just that.

After completing the "understanding" of the sprout, ordinary netizens actually don't pay much attention to the details of Qing Ning Group's subsequent expansion. They only know that Qing Ning Group is very impressive.

The key is that it dropped a shock bomb in the Chinese pharmaceutical industry.

The public sector is fine, after all, droughts and floods guarantee harvests, but for those pharmaceutical giants who also belong to the private camp, well, let's call them pharmaceutical giants, the threat they feel is obvious.

For example, Fanxing Group.

When Qing Ning Group acquired Hengrui Pharmaceuticals, Fanxing felt a budding threat. Unexpectedly, just over a month later, Qing Ning Group made another move.

And it’s a massive investment of nearly 20 billion.

Three acquisitions before and after made Qingning Group grow from scratch and become a super giant in the Chinese pharmaceutical industry, surpassing established competitors such as Fanxing Pharmaceutical in one fell swoop.

It is impossible for Fanxing Group not to panic.

But there is no point in panic. As mentioned before, in the pharmaceutical industry, mergers and acquisitions are one of the main ways. Whoever has strong financial strength will have the confidence to speak.

And it's obvious.

The old Fanxing Group obviously cannot compare with Suiya in terms of financial strength.

The countermeasure that Chen Chang, chairman of Fanxing Group, can think of is to use the circle and rely on the power of the circle to compete with this unusual opponent, Moya.

Unconsciously, I strengthened my communication and communication with my big brother and elders.

"This crazy acquisition by Qing Ning Group should involve unfair competition, right?" Big Brother meant something.

It's obviously a hint.

To use the card of unfair competition, it interfered with Qing Ning Group’s acquisition of Weichuang and Marui.

"This...China's regulations in this area are very strict."

Chen Chang, however, seemed a little lacking in confidence.

"It is precisely because of the lack of this area that an example is needed to promote the improvement of relevant laws, isn't it? Don't forget, this is Bu Ya's specialty." Big Brother continued to criticize.

Some of the things that Mei Ya does cannot be hidden from those who are interested.

It can even be traced back to the early days of promoting the supervision of data related to map navigation software such as Haode Maps, and later the supervision of the food delivery industry and the protection of personal information privacy.

Faintly, you can almost see the sprouting figures.

From a user's perspective, they are naturally happy to see Moya push for the implementation of these regulations, but in the eyes of people like Big Brother, Moya is undoubtedly going out of line and crossing the line.

Breaking some of the rules they thought they had.

Now, Big Brother is going to treat others the way they are treated.

It's just that the motives are not pure...

"You can give it a try."

Chen Chang's eyes flashed slightly, and he was obviously a little moved, but with his caution, he would definitely not come forward in person. At most, he would instigate some small and medium-sized pharmaceutical companies to cause trouble.

He can just hide behind and watch the show.

It would be gratifying to succeed, but there would be no loss to Chen Chang if he failed.

It can be said to be in an invincible position.

"If you need any help, just ask." Big Brother smiled warmly.

"must!"

The two looked at each other and smiled, resembling two old foxes.

………

Wednesday, July 2nd.

Time has come to July in a blink of an eye, which not only means the beginning of the second half of 2014, but also means that a large number of new blood will join the big family of Sprout.

According to the latest statistics from the Talent Center, the total number of employees in the Germination Department has exceeded 400,000.

Very scary.

Of course, more than one-third of the employees are non-permanent contract workers such as electronics factory workers, courier boys, takeaway boys, online ride-hailing drivers, and store clerks.

It also reflects from another aspect the influence of budding on promoting local employment.

July is also the beginning of the third quarter. As the chairman of the group, the first thing Zhang Shuo has to do is to review and approve the funding applications for the third quarter, which mainly include——

Allocate 4 billion R&D funding to the Fertile Soil Research Institute;

Allocate 4.5 billion operating funds to Mango Group, including 3 billion R&D funds;

Allocate 2 billion operating funds to Nebula Group, including 1 billion R&D funds;

Allocate 500 million operating funds to Jiaoyang Holdings;

Allocate 1.5 billion operating funds to Qing Ning Group, including 1 billion special research and development funds;

Allocate 500 million operating funds to the headquarters of the Sprout Group, including the operating expenses of the property management department.

A total of 13 billion funds.

In addition to fixed allocations, in the second quarter that just passed, Sprout Group also had several large expenditures, mainly including -

In early April, a huge amount of 22 billion was allocated to Nebula Group, mainly for the acquisition of Mada Qiqi and the subsequent construction of the Shancheng aviation engine production base;

In mid-May, a huge amount of 26 billion was specially allocated to Qing Ning Group for the acquisition of Hengrui Pharmaceutical;

In late June, 27 billion was allocated to Daosui Group and participated in a 30 billion capital increase;

Not long ago, another huge amount of 17 billion was allocated to Qing Ning Group for the acquisition of two companies, Marui Medical and Vitron Medical.

After three months, the cumulative use of special funds reached 92 billion.

In one fell swoop, all the savings accumulated in the previous quarter were wiped out.

Fortunately, the Germination System is not standing still. While various expenses are huge in the second quarter, hematopoietic machines such as Maili Group, Qinghe Group, and Weizhong Group are also continuing to operate.

Then huge revenue was achieved.

In the second quarter of 2014, Qinghe Group turned over profits of 27.5 billion, Maili Group turned over profits of 21 billion, and Weizhong Group turned over profits of 3.5 billion.

The total profit turned in was 52 billion.

This means that without any non-recurring income, Sprout Group still achieved a net profit of nearly 900 million in a single day in the second quarter.

It’s really a bit scary!

Although there are no non-recurring gains in the profits that Qinghe Group turned over this time, it still achieved a profit growth of more than 30% in a single quarter, which is very scary.

This chapter is not over yet, please click on the next page to continue reading! On the contrary, the profit of Maili Group has experienced a seasonal decline.

With the increase in registered capital and business expansion, Weizhong Group has also embarked on a rapid development track. Although its single-quarter profit is only 3.5 billion, it has also achieved a profit growth rate of more than 20%.

It can be seen that the development potential is still huge.

--slightly--

[Level]: 10,000/100 million)

【Cash】: 28.3 billion

[Loans]: 24.5 billion (bank loans) 10 billion (corporate bonds) 8.4 billion (overseas loans)

[Affiliates]: Qinghe Group, Qingcheng Group (%), Pinxixi Group (90%), Maili Group, Daosui Group (90%), Mango Group, Weizhong Group, Jiaoyang Holdings, Nebula Group,

Lime Group

--slightly--

In just one quarter, more than 20 million experience points have been added.

At this rate, the entrepreneurial level will definitely be raised to level 12 next year, but I don’t know what surprises the system will bring to Zhang Shuo by then.

It’s still worth looking forward to.

With the full implementation of Nebula Group and Qing Ning Group, the "3 3 1" group subsidiary model of Sprout Group has also been upgraded to the "3 3 3 1" model.

The overall strength has risen to a new level.

It is a pity that whether it is Mango Group, Nebula Group, or Lime Group, they still need blood transfusions from the group headquarters and cannot be completely independent.

In comparison.

Among the three group subsidiaries, Qing Ning Group, which was established the latest, may be the first to become independent.

Because whether it is Hengrui Pharmaceutical, Weichuang Medical, or Marui Medical, they were already in a profitable state before they were acquired by Qing Ning Group.

It's just that the profit level is average.

In the third quarter, Sprout Group's allocation to Qing Ning Group was mainly used for integration expenses after the acquisition, and then for research and development expenses, which accounted for the bulk.

This is also an "old trick" of sprouting.

No matter which field we enter, we always use R&D as the core support. By continuously investing in R&D and recruiting talents, we can achieve breakthroughs in technology and process.
To be continued...